Mar. 27 at 10:54 AM
$VIRX Nana-val looking promising in EBV lymphoma trials. Positive data points to potential breakthrough. Company's pivot to focus resources on lymphoma program seems strategic. Watching closely for next clinical updates. well-written article: https://beyondspx.com/article/viracta-therapeutics-virx-navigating-the-challenges-and-opportunities-in-virus-associated-cancers